A Study of the Role of Therapeutic Contact Lenses in Drug Delivery by Fung, Evonne Yuewai et al.
 1
 
 
 
 
 
 
 
 
 
 
 
Final Project: 
 
A Study of the Role of Therapeutic Contact Lenses in Drug Delivery 
 
 
 
BEE 453:  
Computer-Aided Engineering:  
Applications to Biomedical Processes 
 
 
 
 
 
 
 
 
Group 1: 
Evonne Yuewai Fung 
Jennifer Lee 
Anita Tong 
Baotram Tran 
Yuk Yee (Amy) Yau 
 
 
 
 2
A Study of the Role of Therapeutic Contact Lenses in Drug Delivery 
 
1.0  Executive Summary 
Glaucoma is an optical condition caused by pressure build up in the eye and is the leading 
cause of blindness.  Current methods to treat glaucoma include medicated eye drops and oral 
medication, which are both inefficient methods of administration.  Most of the medication in eye 
drops does not reach the target tissue.  In addition, when taken orally, much of the drug circulates 
in the bloodstream instead of reaching the eye.  This is a potential problem since drugs used to 
treat glaucoma, such as timolol maleate, are also prescribed to elevate hypertension.  To avoid 
possible side effects, researchers have developed a novel method of drug delivery that involves 
enclosing the drug in the contact lens to be worn directly over the eye.  The drug-encapsulated 
contact lens can deliver the drug to the target tissue more effectively.   
This paper focuses on the drug delivery of the therapeutic contact lens in the treatment of 
glaucoma using a computer-simulated model created by FIDAP, a computational fluid dynamic 
software.  The problem is modeled as mass transfer of timolol maleate over four layers (lens, 
tear, cornea, and aqueous humor) of an axis-symmetric cylindrical slab.  Results show that with 
an initial concentration of 7 mg/g contact lens in the contact lens, the minimum effective 
concentration of 1.8 µg/mL is achieved in the aqueous humor layer after 45 minutes.  The 
contact lens continues to deliver the drug into the eye at above this concentration for another 75 
minutes before dropping below the minimum effective concentration at 1.5 hours. Sensitivity 
analysis shows that cornea diffusivity is the most important parameter in the solution.   
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2.0 Introduction  
Glaucoma is the leading cause of blindness in the United States (1).  According to the 
Center for Disease Control and Prevention, over 8.7 million doctors’ visits a year are glaucoma-
related.  Glaucoma refers to a group of diseases that gradually cause blindness.  In the most 
common case of glaucoma, the trabecular network or the filtering drain in the eye is clogged.  
Normally, the aqueous humor, the fluid that nourishes the eye and keeps the cornea hydrated, 
drains out of the eye via this network.  Due to the blockage, the aqueous humor cannot exit the 
eye as fast as the rate the ciliary body produces the fluid.  This leads to fluid pressure build up 
and can damage the optic nerve in the eye, causing blindness (2).   
Fortunately, with the proper treatment, blindness can be prevented in 90% of the cases 
(3).  Conventional treatments included medicated eye drops, medication in pill form, laser and 
traditional surgery, or a combination of these methods.  Recent studies show that therapeutic 
contact lens is another possible effective method of treating glaucoma (4).  This study focuses on 
the use of hydrogel contact lens that contains encapsulated nanoparticles of a drug called timolol 
maleate as a treatment of glaucoma.  Timolol maleate lowers the fluid pressure in the eye by 
reducing the production of the aqueous humor by the ciliary body (5).  Thus, as long as the drug 
enters the aqueous humor, it will be able to act on the ciliary body.  Drug delivery via therapeutic 
contact lens is more efficient and preferable than the eye drops because the drug is directed to the 
aqueous humors instead of being absorbed by other surrounding tissues of the eye (12). 
 
 
3.0  Objectives 
  The objective of this paper is to model the drug delivery of timolol maleate from a 
hydrogel contact lens into the aqueous humor of the eye in the treatment of glaucoma.  To 
stimulate the mass transfer of the drug from the contact lens, through the tear layer, the cornea, 
into the aqueous humor, a computational fluid dynamics software, FIDAP, is utilized.  The 
geometry is modeled and meshed using GAMBIT, a preprocessor for FIDAP.  From this 
computational model, FIDAP is used to solve the mass transfer problem using a finite element 
method.  The computational model is used to determine whether the contact lens method could 
deliver the minimum effective concentration needed in the aqueous humor.  In addition, the 
effectiveness of this novel delivery method is compared with the traditional eye drop method of 
delivery. 
 
 
4.0 Project Schematic: 
 The contact lens poly(HEMA/200MAA), is a cross-linked polymer capable of 
encapsulating drug molecules such as timolol maleate, within its porous matrix.  Timolol maleate 
is released from the pores when the matrix swells as it is exposed to the eye.  The drug is 
controlled-released and delivered to the affected site via diffusion through the different layers of 
the eye.  From the cornea of the eye, timolol maleate reaches the aqueous humor to help reduce 
fluid produced by the eye and drain fluids already present in the eye.  The overall effect is the 
ease of pressure build up in glaucoma patients.   
 
4.1 Assumptions: 
• There is homogenous distribution of nanoparticles (drug packets) in contact lens. 
• There is axis-symmetric dimensional drug flow. 
 4
• There is no mass flow from the contact lens to the eyelid. 
• There is negligible contact resistance between each interface; ie. disregard K*, the partition 
coefficient.  
• Constant properties in all layers. 
• The diffusivity value for the cornea is the weighted average of the diffusivity values of the 
two layers composing the cornea: the epithelium and the stroma. 
• The elimination of the drug in the tear and in the aqueous humor is close to the elimination 
(drug reaction) rate in water. 
• Neglect evaporation of water from the eye and the effect of blinking. 
 
4.2 Geometry 
 The model is developed by considering the mass diffusion of timolol maleate.  A four-
layered axis-symmetric slab is used to simplify the geometry of the problem.  The slab consists 
of four layers: the contact lens (0.0105 cm) (6), the film of tear (7x 10-7 cm) (7), the cornea (0.05 
cm) (8), and the aqueous humor (0.225cm) (9).  The aqueous humor layer is modeled as semi-
infinite and thus the flux at the end of the aqueous humor layer.  Figure 1 shows the model 
schematic with the labeled entity names used in FIDAP.   
 
 z 
C(t = 0) = 0 dc/dt = 0 along all edges Note: Not to  
scale r
cornea tear contact 
lens 
“cornea humor” 
“interface” 
“tear lens” 
“cornea edge”
“tear 
edge” 
“cornea center” “tear 
center” 
“humor edge” “lens edge” 
aqueous 
humor “lens front” “humor end” 
dc/dt 
= 0 dc/dt 
= 0 
“humor center” “lens center” 
 
Figure 1: Model schematic with labeled layers, entity names, and boundary and initial conditions. 
   
 
5.0  Solution Validation 
Figures 2 and 3 show two solutions obtained from two different meshes for a node on the 
cornea-humor interface.  Both graphs show a similar shape (initial steep increase followed by a 
slightly slower decline to zero), and the highest concentrations of the graphs is within 10% 
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difference (6.01%1) of one another.  This shows that our solution is not dependent on mesh size.  
The crude mesh is used in all subsequent analyses. 
 
 
Figure 2: Graph for cornea-humor interface for a cruder mesh (total time = 15 hrs = 54000s). 
 
 
Figure 3: Graph at cornea-humor interface for a finer mesh (total time = 5 hrs = 18000s). 
 
 
6.0 Results and Discussion 
                                                 
1  calculation: %01.6
17120.0
|16091.017120.0|
crude
|fine - crude|  difference % =−==  
 6
The objective of this project is to design a contact lens that can deliver a minimum of 1.8 
µg/mL of timolol maleate into the aqueous humor.  This is the minimum effective concentration 
necessary before the interior fluid pressure starts to decrease.  FIDAP calculations with the crude 
mesh (Figure 4) shows that the maximum diffused concentration is 2.4233 µg/mL of timolol 
maleate in the aqueous humor.  This concentration is attained after 45 minutes of continuous 
application.  In addition, the contact lens can be removed after drug concentration has decreased 
below 1.8 µg/mL, which occurs at 1.5 hours after application.  Thus, the contact lens can deliver 
an effective amount of timolol maleate with greater efficiency than eye drops.  Eye drops require 
several applications per day, with much of the drug lost through tear flow..   
 
 
Figure 4: plot of the concentration at the end of aqueous humor layer by using the crude mesh. 
 
Two contour graphs are produced at two different times within the 20-hour run-time 
period.  The contour graph at 7 hours (Figure 5) shows that there is a high amount of drug 
concentrated at the outermost layers (left side of the graph) and a low amount in the aqueous 
humor layer.  This dispersed concentration is due to the large difference between the diffusion 
rates in the lens and tear layers (3 orders of magnitude).  Although it cannot be seen at this 
magnification, most of the drug has diffused out of the lens and concentrated at the cornea due to 
the low diffusivity constant of the cornea layer (5.429x10-7 cm2/s). 
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Figure 5: A contour representation of the axis-symmetric model at 7hrs of total reaction time.   
 
However, at 15 hours (Figure 6), the contour graph showed that most of the drug has 
been eliminated and the concentration has dropped significantly.  The concentration in Figure 6 
is much lower than in Figure 5.  However, timolol maleate concentration in the aqueous humor is 
more evenly distributed than Figure 5..  These two figures records the diffusion process of the 
drug from the contact lens into the aqueous humor. 
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Figure 6: A contour representation of the axis-symmetric model at 15 hrs of total reaction time. 
 
 
7.0  Sensitivity Analysis 
In order to determine the effects of various properties on the solution, the values for the 
cornea diffusivity, tear diffusivity, elimination rate in humor, elimination rate in tear, and initial 
concentration of timolol maleate are varied.  The original diffusivity and reaction rate constants 
are both decreased and increased by a magnitude of 10.  The initial concentration of the drug is 
varied with a lower and higher value.  The effect of this change in parameters on the peak 
concentration is observed for the cornea-humor interface and near the end of humor. 
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Effect of Parameter Values on Peak Concentration of 
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Figure 7: Effect of ten-fold increase and decrease of parameter values on peak concentration of timolol 
maleate near end of the aqueous humor layer.  The original values are shown in green. 
 
The varying of the parameters on the peak concentration show a similar trend in both the 
cornea-humor interface and near the end of the aqueous humor.  Therefore, the analysis of the 
each of the parameters is only done on the concentration change in the cornea-humor interface 
(for the graph on the cornea-humor interface, refer to Figure C3 in the appendix).  The general 
relationship is that an increase in diffusivity values increases the peak concentration, while an 
increase in elimination rates decreases the amount of drug that can reach the end of the aqueous 
humor. 
 
7.1  Cornea diffusivity 
The diffusivity coefficient in the cornea layer is chosen in our sensitivity analysis because 
of the difficulty in obtaining one consistent value for the cornea.  The cornea layer is actually 
made up of several different layers, primarily with the stroma layer (diffusivity = 6.022×10-7 
cm2/s) comprising 90% of total corneal thickness and the epithelial layer (diffusivity = 8.72 ×10-9 
cm2/s) comprising 10%.  The weighted average diffusivity value 5.43 ×10-7 cm2/s is used for our 
model. 
From the figure, it can be seen that cornea diffusivity is an important factor in the 
solution.  While all of the parameters are changed by the same order of magnitude, the change in 
cornea diffusivity has the greatest effect on the peak concentration.  Specifically, when the 
cornea diffusivity values are plotted on a logarithmic scale, it shows a positive linear relationship 
with the concentration, as seen in figures C1 and C2. 
The results from this sensitivity analysis suggest that in the GAMBIT model, the cornea 
layer should have been treated as two separate layers (an epithelial and a stoma layer) with their 
respective diffusivity values for more accurate results. 
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7.2  Tear diffusivity 
The diffusivity of the drug in tear is assumed to be the same as the diffusivity of the drug 
in water (diffusivity = 5×10-5 cm2/s), so sensitivity analysis is done to see if this was a valid 
assumption.  In the original solution, the graph peaked around 3300s at a concentration of 
0.17120 mg/mL at the cornea-humor interface.  When tear diffusivity is lowered, the graph 
reaches a maximum slightly faster, at 2900 s, with a concentration of 0.15783 mg/mL.  There is a 
7.81% difference in the maximum concentration achieved.  Similarly, there is a 7.80% difference 
in the maximum concentration at the end of the humor layer when tear diffusivity is changed.  
This shows that the final solution is not very sensitive to changes in the value for tear diffusivity.  
However, when the tear diffusivity values is increased by a factor of ten, the peak concentration 
increased by 64%.  The assumption that the drug diffusivity in the tear is the same as that in the 
water, is only useful if the actual diffusivity value in the tear is lower than the drug diffusivity in 
water. 
 
7.3  Drug elimination rate in humor 
The other reaction term in our drug concentration model is the rate of elimination of the 
drug in the aqueous humor layer.  Figure 7 shows a reasonable decrease in peak concentration as 
elimination rate increases.   Decreasing and increasing the elimination rate by ten-fold, resulted 
in a 21.4% and 18.5% difference in peak concentration respectively.  This suggests that the 
solution is highly sensitive to the rate of drug elimination in the humor. 
 
7.4  Drug elimination rate in tear 
The original solution at the cornea-humor interface with K= -3×10-3 s-1.  It is evident 
from figure 7 that the ten-fold increase in the reaction rate result in a sharp decrease by 68.3% in 
peak concentration.  Decreasing the rate ten-fold resulted in an 8.2% difference in peak 
concentration.  It can be seen from the difference that the rate of drug elimination in tear is 
crucial to the final solution, especially when the rate is increased. 
 
7.5  Initial concentration 
Sensitivity analysis for initial concentration of the drug in the contact lens is done by 
changing the value from 46.5mg/mL (original) to 40mg/mL and 55mg/ml.  The shape of the 
graphs remains relatively the same, with a 16.2% difference in the maximum concentration at the 
cornea-humor interface.  An increase in initial concentration to 55 mg/mL changes the peak 
concentration by 10.6%.  From Figure 8, it can be concluded that initial concentration has some 
effect on the final solution.  Near the end of the humor, the highest concentration occurs at the 
original initial concentration value obtained from research papers, which indicates that the 
optimal initial concentration is used in our solution. 
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Effect of Initial Concentration on Peak Concentrations
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Figure 8: Effect of initial concentration on peak concentration in both the cornea humor interface and the 
end of humor. 
 
 
8.0  Design Process 
There are eight major criteria for design: economic, sustainability, ethnical, social, 
environmental, manufacturability, health and safety, and political.  These criteria can be grouped 
into three point of views on the product: the manufacturer’s perspective, the consumer’s 
perspective, and the waste collector’s (post-consumer) perspective.  Because these three types of 
people have different priorities and needs, they place different requirements and limitations on 
the product.  Thus, the ultimate design is a compromise that maximizes the criteria set by all 
three groups. 
 
The Consumer 
Five out of eight design criteria concern the consumer: economic, health and safety, 
social, ethnical, and political.  This is expected because the consumer is the principal 
consideration in a design – the product is made to solve their problem.  In designing contact 
lenses for drug delivery, anyone can be the target patient.  Economically, since there are people 
in the entire range of economic sectors, the goal is to design a product that is affordable by all.   
Currently regular disposable daily contact lenses are priced at approximately $20 per box of 30 
lenses and glaucoma eye-drops at approximately $8-20 per 5 mL of 0.25% timolol maleate (10), 
(11).  Our aim would be to design a product that can be sold at a comparable price.  
Economically in another sense, customers expect the product to be efficient.  Users will expect 
drug-delivering contact lenses to be effective and easy to wear.  It should also be disposable, 
since glaucoma does not occur so often that a person will need reusable lenses at hand.  
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Furthermore, single-use lenses will be more convenient for the user.  Customers will be looking 
for something inexpensive that works. 
This product does not have many social or ethical concerns, with the possible exception 
of animal/human testing.  However, since it is a drug delivery system, there are several important 
health and safety considerations.  The dosage that each contact lens should contain and how long 
it can be worn are two of the most crucial, because a concentration that is too high will cause a 
stinging sensation in the eye and a concentration that is too low will not alleviate the pressure 
buildup.  Ultimately, clinical experiments will need to be carried out to determine these 
parameters.  Whether the product can be used on patients with previous eye surgery or other eye 
conditions should also be investigated.  Finally, children or the elderly might be recommended 
not to use this product. 
 
The Manufacturer 
The manufacturer is mainly concerned with manufacturability, sustainability, economy, 
and safety.  Manufacturability includes various concerns: availability of the necessary 
components, costs of production, shelf life of product, and required facilities or technologies.  
Ideally, the product should be made from readily available standardized parts, can be stored for a 
long time, can be manufactured with existing technologies at accessible facilities, and is 
inexpensive to produce.  Contact lenses for drug delivery is not yet available in the market.  
However, they have been successfully manufactured at laboratories and experimented on with 
rabbits.  It is very likely that this product will become commercially available in the next ten 
years.   
 Economy is a criteria valued by the manufacturer as well because no one would want to 
sell a product that cannot bring a profit.  Related to this is the sustainability of the product: 
manufacturers want to be assured that the design is one that would not become obsolete for a 
long time and can adapt new technologies to make it last in the market.  Finally, safety is also of 
importance to manufacturers.  Automated plants would be optimal if possible, but if not, safety 
precautions should be outlined and safety facilities built (for example, fume hoods for volatile 
hazardous chemicals). 
 
The Waste Collector 
 After the device has served its purposes, the final recipient of the device will be the waste 
collector.  Again, the product should be made safe for disposal.  Since this product is intended to 
be used by everyday people, it should be made so that it can be treated like normal garbage.  We 
expect that drug-delivering contact lenses will not be a problem in this aspect since normal 
contact lenses can be disposed of through conventional waste treatment methods.  Finally, 
product biodegradability is also a concern.  The materials used to produce the contact lenses 
should meet environmental standards.  In essence, a good design would be one that solves 
problems without causing any in the process. 
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9.0       Appendix A 
 
9.1 Governing Equations 
 The species equation in cylindrical coordinates is used.  There is no convection and no 
variation in theta direction.    
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 A governing equation is needed for each layer since the properties vary for each.  In 
addition, there is an elimination term for the tear and the aqueous humor, which is treated as a 
zeroth order reaction term in the governing equation.   There is no reaction in the lens and the 
cornea.    
 
9.2 Boundary Conditions 
 The flux is zero for the following boundaries: “lens center,” “lens front,” “lens edge,” 
“humor center,” “humor end,” “humor edge,” “cornea edge,” and “cornea center.”  These 
conditions are set because the geometry of the slab has an axis of symmetry along the center and 
there is no drug leaving the edges or evaporating from the contact lens.   Additionally, since the 
aqueous humor is semi-infinite, the flux and concentration at the “humor end” is zero.    
 
9.3 Initial conditions 
 The initial concentration of the drug in the contact lens is 46.5mg/cm3 (4) and zero for 
the other three layers. 
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9.4  Gambit Mesh 
 
 
 
9.5 Input parameters 
 
Constants Used 
Table A1 shows the constants used and where they were obtained.  These values were 
obtained from journal articles and the majority of them were obtained from experiments done on 
rabbit eyes.  Often a range of values was found, usually within the same order of magnitude.  In 
these cases, the average value was taken.  In the sensitivity analysis, the effect of this assumption 
was tested.  
 
Table A1: A summary of the constants used. 
Description Location Value Units 
Obtained 
from 
initial concentration lens 7 mg/g dry hydrogel (13) 
diffusivity tear 1.40E+09 cm2/s (14) 
diffusivity cornea 7.35E-07 cm2/s (15), (16) 
diffusivity humor 
 
5E-5 cm2/s 
 
(17) 
diffusivity lens 9.9 E -9 cm2/s (18) 
reaction rate (elim) tear 0.18 min-1 (18) 
reaction rate (absorp) cornea 0   
reaction rate (elim) humor 0.32 hr-1 (18) 
thickness lens 0.105 mm (6) 
thickness tear 7 µm (7) 
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thickness cornea 0.5 mm (8) 
thickness humor 2.25 mm (9) 
diameter lens 0.675 cm (6) 
 
Problem Menu  
Axis-symmetric - we are taking the center of the contact lens to be the axis  
   of symmetry (see Geometry section) 
Incompressible - tears is assumed incompressible (constant density) 
Transient - we are interested in the transient state of the problem 
Laminar - tear flow is laminar (and not turbulent) 
Linear - eliminates second derivative (convective term) in GE 
Newtonian - the fluid is Newtonian (behaves like water). 
NoMomentum - momentum is not considered in the problem.   eliminates  
   velocity (and thus convective) terms. 
Isothermal - heat equation is not solved in the problem (assumes  
   constant temperature). 
Fixed - surfaces in geometry are fixed (no free surface). 
NoStructural - includes any entity that is defined as subject to elastic  
   deformation 
NoRemeshing - mesh cannot be changed. 
SinglePhase - flow has only one phase. 
 
 
Solutions Menu  
SEGR.  = 100 -  
Relaxation Factor (HYBR) -  
 
Time Integration Menu  
Time Integration = backward - uses implicit method (t + ∆t), which is more  
   stable. 
No.  Time Steps = 400 - solution has fixed number of time steps 
Starting Time = 0 - starting time is at 0s 
Ending Time = 54000 - ending time is at 7200s (we are modeling the  
   linear portion of drug release; 60% in 2 hours) 
Time Increment = 250 - each time increment is 250s 
Time Stepping Algorithm  
FIXED = 1 
- variable step integration, DT is time increment    
   for initial NOFIXED time steps only 
Variable Window: WINDOW - allows more flexibility in the error control for  
   the VARIABLE time increment option. 
No.  fixed steps: NOFIXED - number of fixed increment backward Euler  
   steps, default= 3 
 
Defining Entity  
name type [info] – description 
lens solid [species = 1, MDiff = “drug in lens”] – contact lens 
 16
tear solid [species = 1, MDiff = “drug in tear”] –tear film  
cornea solid [species = 1, MDiff = “drug in cornea”] – cornea 
humor solid [species = 1, MDiff = “drug in humor”] – aqueous humor 
lens front plot - boundary between air and lens 
lens center plot - axis in the lens layer 
lens edge plot - lens layer at the circumference 
tear center plot - axis in the tear layer 
cornea center plot - axis in the corneal layer 
tear edge plot - tear film at the circumference 
tear lens plot - boundary between contact lens and tear film 
interface plot - boundary between tear film and cornea 
cornea end plot - boundary where cornea meets aqueous humor in eye 
cornea edge plot - cornea at the circumference 
cornea humor plot - boundary between cornea and humor 
humor center plot - axis in the humor layer 
humor end plot - humor at the circumference 
 
Defining Property – Diffusivity  
tear drug = 14 × 108 cm2/s - diffusivity of the drug in tear film 
tear cornea = 0.735 × 10-6 cm2/s - diffusivity of the drug in cornea layer 
 
 
 
Initial Conditions  
Tear - species, constant at 0 
Cornea - species, constant at 0 
interface - species, constant at 0 
 
Boundary Conditions - BCFLUX  
tear center - species, constant at 0 
cornea center - species, constant at 0 
cornea end - species, constant at 0 
cornea edge - species, constant at 0 
tear edge - species, constant at 0  
tear lens - species, constant at 0.5589 mg/cm2 (total concentration over  
   surface area of contact lens – this needs to be adjusted to 60% of  
   concentration over total surface area) 
interface - species, constant at 0 
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10.0 Appendix B: Results- Additional Graphs 
 
 
Figure B1. A contour representation of the axis-symmetric model at 45 minutes of total reaction time for the 
crude mesh when drug is at maximum concentration in humor layer. 
 
 
Figure B2. A contour representation of the axis-symmetric model at 1.5 hours of total reaction time for the 
crude mesh when drug concentration is less than the minimum effective concentration.  Note that the color 
gradient between the two contours does not match up. 
 
The initial concentration history plot for the lens layer (Figure B3) shows that 
concentration indeed starts at 46.5 mg/mL.  It decreases sharply from 0 seconds to 3.1 hours, 
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then slowly converge to zero after 6 hours.  Because of its linear portion at the initial 3 hours of 
application, our contact lens drug delivery system can possibly be modeled as steady state 
diffusion. 
 
 
Figure B3. A history plot of concentration at the lens layer using the crude mesh.  At about 11220 seconds or 
3.1 hours, the diffusive rate starts to decrease dramatically and reach zero around 21900 seconds or 6.1 hrs. 
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11.0 Appendix C: Sensitivity Analysis- Additional Graphs 
Sensitivity analysis
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Figure C1: Logarithmic relationship between cornea diffusivity and peak concentration near the end of the 
humor. 
 
Sensitivity analysis
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Figure C2: Logarithmic relationship between cornea diffusivity and peak concentration at the cornea-humor 
interface. 
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Effect of Parameter Values on Peak Concentration of 
Timolol Maleate in Cornea-Humor Interface
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Figure C3: Effect of ten-fold increase and decrease of parameter values on peak concentration of timolol 
maleate at the cornea-humor interface.  The original values are shown in above the bars. 
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12.0 Appendix D – Input File 
 
/ 
/  INPUT FILE CREATED ON 10 Apr 04 AT  17:47:50 
/ 
/ 
/ ***  FICONV Conversion Commands ***  
/ ***  Remove / to uncomment as needed 
/ 
/  FICONV(NEUTRAL,NORESULTS,INPUT) 
/  INPUT(FILE= "april9.FDNEUT") 
/  END 
/  *** of FICONV Conversion Commands 
/ 
TITLE 
 
/ 
/ ***  FIPREP  Commands *** 
/ 
FIPREP 
 PROB (AXI-, INCO, TRAN, LAMI, LINE, NEWT, NOMO, ISOT, FIXE, NOST, NORE, 
SING, 
       SPEC = 1.0) 
 EXEC (NEWJ) 
 SOLU (SEGR = 100, VOLC = 0.100000000000E-02, SCHA = 0.000000000000E+00) 
 TIME (BACK, NSTE = 360, TSTA = 0.000000000000E+00, TEND = 18000.0, DT = 
50.0, 
       FIXE) 
 RELA (HYBR) 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.3000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00 
 ENTI (NAME = "cornea", SOLI, SPEC = 1.0, MDIF = "drug in cornea") 
 ENTI (NAME = "humor", SOLI, SPEC = 1.0, MDIF = "drug in humor", SPEC = 1.0, 
       MREA = "humor") 
 ENTI (NAME = "lens", SOLI, SPEC = 1.0, MDIF = "drug in lens") 
 ENTI (NAME = "tear center", PLOT) 
 ENTI (NAME = "cornea center", PLOT) 
 ENTI (NAME = "cornea humor", PLOT) 
 ENTI (NAME = "cornea edge", PLOT) 
 ENTI (NAME = "tear edge", PLOT) 
 ENTI (NAME = "tear lens", PLOT) 
 ENTI (NAME = "interface", PLOT) 
 ENTI (NAME = "lens center", PLOT) 
 ENTI (NAME = "lens front", PLOT) 
 ENTI (NAME = "lens edge", PLOT) 
 ENTI (NAME = "humor center", PLOT) 
 ENTI (NAME = "humor end", PLOT) 
 ENTI (NAME = "humor edge", PLOT) 
 ENTI (NAME = "tear", SOLI, SPEC = 1.0, MDIF = "drug in tear", SPEC = 1.0, 
       MREA = "tear") 
 DIFF (SET = "drug in tear", CONS = 0.500000000000E-04) 
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 DIFF (SET = "drug in cornea", CONS = 0.543000000000E-06) 
 DIFF (SET = "drug in humor", CONS = 0.500000000000E-04) 
 DIFF (SET = "drug in lens", CONS = 0.990000000000E-08) 
 REAC (SET = "tear", CONS, TERM = 1, KINE) 
  -0.3000000000E-02,  0.0000000000E+00,  0.0000000000E+00,  0.1000000000E+01, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.2730000000E+03 
 REAC (SET = "humor", CONS, TERM = 1, KINE) 
  -0.1000000000E-03,  0.0000000000E+00,  0.0000000000E+00,  0.1000000000E+01, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.2730000000E+03 
 BCNO (SPEC = 1.0, ENTI = "humor end", CONS = 0.000000000000E+00) 
 BCFL (SPEC = 1.0, ENTI = "cornea edge", CONS = 0.000000000000E+00) 
 BCFL (SPEC = 1.0, ENTI = "tear edge", CONS = 0.000000000000E+00) 
 BCFL (SPEC = 1.0, ENTI = "humor edge", CONS = 0.000000000000E+00) 
 BCFL (SPEC = 1.0, ENTI = "lens front", CONS = 0.000000000000E+00) 
 BCFL (SPEC = 1.0, ENTI = "lens edge", CONS = 0.000000000000E+00) 
 ICNO (SPEC = 1.0, CONS = 46.5, ENTI = "lens") 
 ICNO (SPEC = 1.0, ZERO, ENTI = "tear") 
 ICNO (SPEC = 1.0, ZERO, ENTI = "humor") 
 ICNO (SPEC = 1.0, ZERO, ENTI = "cornea") 
END 
/  *** of FIPREP Commands 
CREATE(FIPREP,DELE) 
CREATE(FISOLV) 
PARAMETER(LIST) 
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